Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia

Leukemia Research

Volumn 30, Issue 4, 2006, Pages 407-413

  Xu, Wen Lin ^a   Shen, Hui Ling ^a   Ao, Zhong Fang ^b   Chen, Bao An ^c   Xia, Wei ^b   Gao, Feng ^c   Zhang, Yong Ning ^a  

^a JIANGSU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; P glycoprotein (P gp); Refractory relapse; Tetrandrine

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TETRANDRINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RISK; CANCER THERAPY; CARDIOTOXICITY; CELL STRAIN K 562; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG RETENTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFECTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REFRACTORY ANEMIA; RELAPSE; REMISSION; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLISOQUINOLINES; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; P-GLYCOPROTEIN; RECURRENCE;

EID: 32844461208     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.08.005     Document Type: Article

References (33)

1. K. Stahnke, J. Boos, C. Bender-Gotze, J. Ritter, M. Zimmermann, and U. Creutzig Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia Leukemia 12 1998 1534
2. H.T. Steinmetz, A. Schulz, P. Staib, C. Scheid, A. Glasmacher, and A. Neufang Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML Ann Hematol 78 1999 418
3. M.M. van den Heuvel-Eibrink, E.A.C. Wiemer, M.J. de Boevere, B. van der Holt, P.J.M. Vossebeld, and R. Pieters MDR-1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia Blood 97 2001 3605
4. F. Casale, V. D'Angelo, R. Addeo, M. Caraglia, S. Crisci, and R. Rondelli P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia Oncol Rep 12 2004 1201
5. A. Tafuri, C. Gregorj, M.T. Petrucci, M.R. Ricciardi, M. Mancini, and G. Cimino MDR-1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia Blood 100 2002 974
6. C.L. Willman Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR-1) Leukemia 10 1996 S33
7. A.F. List Multidrug resistance: clinical relevance in acute leukemia Oncology (Huntingt) 7 1993 23
8. R.J. Arceci Clinical significance of P-glycoprotein in multidrug resistance malignancies Blood 81 1993 2215
9. T. Litman, T. Zeuthen, T. Skovsgaard, and W.D. Stein Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity Biochim Biophys Acta 1361 1997 169
10. Z.L. Liu, T. Hirano, S. Tanaka, K. Onda, and K. Oka Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells J Pharm Pharmacol 55 2003 1531
11. J.H. Fang, and Y.H. Fang Tetrandine: pharmacology and clinical usefulness Chin Pharmaceutic 31 1996 454
12. B.D. Cheson, P.A. Cassileth, D.R. Head, C.A. Schiffer, J.M. Bennett, and C.D. Bloomfield Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 8 1990 813
13. H.D. Preisler, and V. Gopal Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment Leuk Res 18 1994 149
14. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649
15. R.J. Arceci, K. Stieglitz, J. Bras, A. Schinkel, F. Baas, and J. Croop Monoclonal antibody to an external epitope of the human MDR-1 P-glycoprotein Cancer Res 53 1993 310
16. C.P. Leith, I.M. Chen, K.J. Kopecky, F.R. Appelbaum, D.R. Head, and J.E. Godwin Correlation of multidrug resistance (MDR-1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-1-/efflux+ and MDR-1+/efflux-cases Blood 86 1995 2329
17. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719
18. E. Estey, S. Kornblau, S. Pierce, H. Kantarjian, M. Beran, and M. Keating A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia Blood 88 1996 756
19. D.A. Rizzieri, V.K. Ibom, J.O. Moore, C.M. DeCastro, G.L. Rosner, and D.J. Adams Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia Clin Cancer Res 9 2003 663
20. R.J. Wells, M.T. Adams, T.A. Alonzo, R.J. Arceci, J. Buckley, and A.B. Buxton Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukaemia: children's cancer group study 2951 J Clin Oncol 21 2003 2940
21. S.M. Kornblau, E. Estey, T. Madden, H.T. Tran, S. Zhao, and U. Consoli Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia J Clin Oncol 15 1997 1796
22. G.J. Ossenkoppele, W.J. Graveland, P. Sonneveld, S.M.G.J. Daenen, D.H. Biesma, and L.F. Verdonck The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients Blood 103 2004 2908
23. J.W. Putney Pharmacology of capacitative calcium entry Mol Interventions 1 2001 84
24. J.T. Cheng Review: drug therapy in Chinese traditional medicine J Clin Pharmacol l40 2000 445
25. P. Sonneveld, A. Burnett, P. Vossebeld, M. Ben-Am, G. Rosenkranz, and C. Pfister Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia Hematol J 1 2000 411
26. E.J. Lee, S.L. George, M. Caligiuri, T.P. Szatrowski, B.L. Powell, and S. Lemke Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukaemia: results of cancer and leukemia group B study 9420 J Clin Oncol 17 1999 2831
27. T.R. Chauncey, C. Rankin, J.E. Anderson, I. Chen, K.J. Kopecky, and J.E. Godwin A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617 Leuk Res 24 2000 567
28. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, and M.R. Melamed Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci USA 86 1989 695
29. C.P. Leith, K.J. Kopecky, I.M. Chen, L. Eijdems, M.L. Slovak, and T.S. McConnell Frequency and clinical significance of the expression of the multidrug resistance proteins MDR-1/P-glycoprotein, MRP1, and LRP in acute myeloid leukaemia: a southwest oncology group study Blood 94 1999 1086
30. M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, and G.J.L. Kaspers Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia Blood 91 1998 2092
31. C.P. Leith, K.J. Kopecky, J. Godwin, T. McConnell, M.L. Slovak, and I.M. Chen Acute myeloid leukemia in the elderly: assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy, a southwest oncology group study Blood 89 1997 3323
32. P. Indolfi, F. Casale, V. D'Angelo, R. Addeo, S. Crisci, and E. Pota P-glycoprotein (p-gp) expression and function as an independent prognostic factor in childhood acute lymphoblastic leukaemia ASCO Meet Abstr 22 2004 8503
33. D.M. van der Kolk, E.G.E. de Vries, W.L.J. van Putten, L.F. Verdonck, G.J. Ossenkoppele, and G.E.G. Verhoef P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia Clin Cancer Res 6 2000 3205